GRF:BME
Grifols SA Class A
€10.00
arrow_downward
-1.77%(-0.18) 1D
Oct 19, 5:20:35 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRF...
Open
€10.13
High
€10.14
Low
€9.92
Mkt. cap
6.02B
Avg. vol.
1.30M
Volume
717.12K
Dividend
2.32%
Quarterly dividend
€0.06
Ex-dividend date
Jun 30, 2026
P/E ratio
15.04
52-wk high
€11.93
52-wk low
€8.43
EPS
€0.67
Shares outstanding
426.13M
No. of employees
25K
Open
€10.13
High
€10.14
Low
€9.92
Mkt. cap
6.02B
Avg. vol.
1.30M
Volume
717.12K
Dividend
2.32%
Quarterly dividend
€0.06
Ex-dividend date
Jun 30, 2026
P/E ratio
15.04
52-wk high
€11.93
52-wk low
€8.43
EPS
€0.67
Shares outstanding
426.13M
No. of employees
25K
News stories
From web sources and news partners
ad-hoc-news.de
·
54 minutes ago
Grifols stock: At EUR 10.01, Grifols stock trades 1.67 percent below the BME close
ad-hoc-news.de
·
7 hours ago
Wall Street Zen cuts rating for Grifols stock to Hold
ad-hoc-news.de
·
1 day ago
Grifols highlights plasma donation gap. Grifols stock trades at EUR 10.08
ad-hoc-news.de
·
2 days ago
Grifols highlights plasma donation gap as Grifols stock last traded at EUR 10.13
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A